Longer-term studies are required to evaluate safety, particularly hepatotoxicity and effects on other hormone-sensitive tissues such as the endometrium, and to formally test whether PR antagonism reverses mammographic density-associated breast cancer risk. Here, PGR is linked to breast carcinoma.